What’s next for Novo Nordisk’s obesity drug CagriSema

What’s next for Novo Nordisk’s obesity drug CagriSema

A version of this article first appeared in CNBC’s Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions. Novo Nordisk isn’t catching a break this year.  Shares of the Danish drugmaker plummeted on Monday after it released data showing that its next-generation obesity drug failed…

Read More
Danaher is tapping the M&A well yet again. But we might have had enough

Danaher is tapping the M&A well yet again. But we might have had enough

Danaher ‘s days in the portfolio may be numbered. We’re again left disappointed after Danaher’s latest acquisition plan failed to inspire Wall Street. Shares of the life sciences giant lost more than 3.5% following Tuesday’s announcement that the company agreed to buy medtech Masimo for $180 per share in cash, or more than $9.6 billion. Masimo…

Read More
How largest health-care educator in US is tackling a growing jobs gap

How largest health-care educator in US is tackling a growing jobs gap

When Steve Beard took on the role of CEO at higher education firm Adtalem Global Education in 2021, the company was undergoing a significant strategic shift. It had identified gaps in the health-care workforce pipeline, which were expected to grow. That led Adtalem to exit its other education business units and focus solely on health-care education. …

Read More